Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2001

View Archived Issues

Schering AG provides update at annual press conference

Encouraging preclinical results reported for Titan's controlled-release buprenorphine

NVP-DPP-728 improves glucose tolerance in rat model

Schering AG's liver-specific contrast agent approved in Sweden

NeoPharm files IND for liposomal mitoxantrone

Yamanouchi and Pharmacia amend celecoxib agreement for Japan

New vaccine targets for cancer-causing strains of HPV identified

Oxeze Turbuhaler approved in Canada for control and relief of asthma symptoms

NPS and AstraZeneca join forces in drug development alliance

Dainippon's AR inhibitor improves diabetic neuropathy in laboratory study

Phase I/II evaluation of Titan's Pivanex begins in liver cancer

CPMP issues positive opinion for Fabrazyme

Micafungin heading for regulatory filings this year and next

PG-TXL proves superior to free paclitaxel against human colon cancer xenografts

AACR presentation points to potential new indication for ABX-IL-8: melanoma

AACR news: preliminary phase I/II results with Vaxid indicate good safety, immunogenicity

PEG-Intron/Rebetol combination for hepatitis C treatment approved in E.U.

Voluntary withdrawal of injectable anesthesia drug by Organon

Tumstatin exerts antiangiogenic and apoptotic effects according to preclinical studies

Drotrecogin alfa (activated) granted FDA priority review for severe sepsis

European approval granted for Sanofi-Synthelabo's Fasturtec

Pyrrolidine-based influenza neuraminidase inhibitors under study at Abbott

Potent and selective MC4 receptor antagonists useful for weight and pigmentation disorders

Japanese researchers describe potential new therapy for diastolic heart failure

Hydroxamic acid-based MMP inhibitors disclosed by Novartis

BASF presents new vitronectin inhibitors and possible uses thereof

Potassium channel blockers targeting the slow delayed rectifier designed by Merck

Glycine-site NMDA receptor antagonists discovered at Gruenenthal

New erythromycin derivatives from Taisho exert potent antibacterial activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...